MacroGenics, Inc. (MGNX)
Develops antibody-based cancer drugs currently in clinical testing
$3.85-0.04%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+143.7%
The outlook
MacroGenics trades at $3.85 with a "Buy" consensus from a small analyst group; the average price target sits roughly 75% above the current level. The stock is positioned midway through its 52-week range with mixed momentum against its moving averages, reflecting neither clear strength nor weakness in recent price action.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 4 analysts
Price trendMixed vs its moving averages
52-week range68% of the way from its 52-week low to high
Price targetAvg target +75% vs current price
Analyst price target
~12-month · 4 analysts$6.75average target+75.3% vs now
Now $3.85
Low $4.00High $9.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$244.7M
52-wk high
$5.08
52-wk low
$1.29
50-day avg
$4.32
200-day avg
$2.68
Trailing P/E
—